Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

NCT02264613 is registered in ClinicalTrials.gov with Aileron Therapeutics, Inc. as lead sponsor.

NCT NCT02264613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02264613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Lead sponsor
Aileron Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2014
Completion date
April 30, 2020
Enrollment
142 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, peripheral t-cell lymphoma, solid tumor